Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Institutional Investors 2017 Q3 Sentiment

January 14, 2018 - By Migdalia James

 Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Institutional Investors  2017 Q3 Sentiment

Sentiment for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) institutional sentiment decreased to 1.03 in Q3 2017. Its down -0.36, from 1.39 in 2017Q2. The ratio worsened, as 125 active investment managers opened new or increased stock positions, while 121 sold and trimmed positions in Jazz Pharmaceuticals PLC. The active investment managers in our partner’s database reported: 53.58 million shares, up from 51.74 million shares in 2017Q2. Also, the number of active investment managers holding Jazz Pharmaceuticals PLC in their top 10 stock positions decreased from 8 to 3 for a decrease of 5. Sold All: 39 Reduced: 82 Increased: 94 New Position: 31.

Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has market cap of $9.00 billion. The firm has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. It has a 24.73 P/E ratio. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain.

The stock increased 1.14% or $1.69 during the last trading session, reaching $150.19. About 787,439 shares traded or 62.72% up from the average. Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) has risen 1.25% since January 14, 2017 and is uptrending. It has underperformed by 15.45% the S&P500.

Analysts await Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) to report earnings on February, 27. They expect $2.63 EPS, up 37.70 % or $0.72 from last year’s $1.91 per share. JAZZ’s profit will be $157.67M for 14.28 P/E if the $2.63 EPS becomes a reality. After $2.93 actual EPS reported by Jazz Pharmaceuticals Public Limited Company for the previous quarter, Wall Street now forecasts -10.24 % negative EPS growth.

Cadian Capital Management Lp holds 8.07% of its portfolio in Jazz Pharmaceuticals Public Limited Company for 1.18 million shares. Putnam Investments Llc owns 8.28 million shares or 2.8% of their US portfolio. Moreover, Senator Investment Group Lp has 2.53% invested in the company for 1.30 million shares. The Ohio-based Gratry & Co Llc has invested 2.42% in the stock. Westfield Capital Management Co Lp, a Massachusetts-based fund reported 1.44 million shares.#img1#

Since January 1, 0001, it had 0 buys, and 16 selling transactions for $2.80 million activity.

Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) Ratings Coverage

Ratings analysis reveals 76% of Jazz Pharmaceuticals’s analysts are positive. Out of 21 Wall Street analysts rating Jazz Pharmaceuticals, 16 give it “Buy”, 0 “Sell” rating, while 5 recommend “Hold”. The lowest target is $124 while the high is $229. The stock’s average target of $179.76 is 19.69% above today’s ($150.19) share price. JAZZ was included in 70 notes of analysts from August 3, 2015. The rating was maintained by Mizuho with “Hold” on Tuesday, December 5. Mizuho maintained the shares of JAZZ in report on Friday, October 13 with “Hold” rating. The firm has “Buy” rating given on Tuesday, September 19 by BMO Capital Markets. Cantor Fitzgerald maintained Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) on Sunday, December 3 with “Buy” rating. The stock of Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) has “Buy” rating given on Thursday, January 11 by BMO Capital Markets. As per Thursday, August 25, the company rating was initiated by Janney Capital. The rating was maintained by Mizuho on Tuesday, February 21 with “Buy”. Mizuho downgraded the stock to “Neutral” rating in Tuesday, November 10 report. As per Wednesday, November 8, the company rating was maintained by RBC Capital Markets. On Wednesday, November 8 the stock rating was maintained by UBS with “Buy”.

More notable recent Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) news were published by: Prnewswire.com which released: “Jazz Pharmaceuticals and Azur Pharma Agree to Combine to Form Jazz …” on September 19, 2011, also Prnewswire.com with their article: “Jazz Pharmaceuticals Announces Third Quarter 2016 Financial Results” published on November 08, 2016, Prnewswire.com published: “Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2016 Financial Results” on February 28, 2017. More interesting news about Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) were released by: Benzinga.com and their article: “Martin Shkreli Thinks Jazz Pharmaceuticals Could Be Worth $20 Billion, While …” published on September 12, 2016 as well as Prnewswire.com‘s news article titled: “Jazz Pharmaceuticals Announces Offering of $500 Million of Exchangeable Senior …” with publication date: August 17, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.